Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1255

—

1efc773e-3975-531c-a91a-e842c50c8561

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • WNT_BETA_CATENIN_SIGNALING+0.352
  • HYPOXIA+0.246
  • MYOGENESIS+0.238
  • GLYCOLYSIS+0.159
  • MITOTIC_SPINDLE+0.155
  • DNA_REPAIR+0.103
  • ANGIOGENESIS+0.095
  • G2M_CHECKPOINT+0.093
  • NOTCH_SIGNALING+0.093
  • HEDGEHOG_SIGNALING+0.088

Top 10 suppressed

  • INTERFERON_GAMMA_RESPONSE-0.462
  • INTERFERON_ALPHA_RESPONSE-0.427
  • ALLOGRAFT_REJECTION-0.419
  • INFLAMMATORY_RESPONSE-0.371
  • IL6_JAK_STAT3_SIGNALING-0.276
  • PEROXISOME-0.269
  • COMPLEMENT-0.259
  • PROTEIN_SECRETION-0.241
  • KRAS_SIGNALING_UP-0.217
  • ANDROGEN_RESPONSE-0.184

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-NC-A5HF-01A-11R-A26W-07
lung-landscapes@6
—cohortSQ10.834
2SRR17866827
colon-landscapes@1
——0.793
3C3N-02288
lung-landscapes@6
—cohortSQ20.791
4SRR2016936
head-neck@1
——0.788
5C3L-02163
lung-landscapes@6
—cohortSQ20.787
6c3b46d4b-4d9f-4d2d-bbca-c0dbd6901e56
melanoma-umap@29
——0.786
720130253.TNBC
breast-umap@18
—E0.778
8TCGA-NC-A5HP-01A-11R-A26W-07
lung-landscapes@6
—cohortSQ10.775
9TCGA-85-8479-01A-11R-2326-07
lung-landscapes@6
—cohortSQ10.772
10BS_C05FKR8X
brain-umap@2
Supratentorial Ependymoma—0.767

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 17 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
WNT_BETA_CATENIN_SIGNALING0.352Inavolisib— uncovered
HYPOXIA0.246Idelalisib— uncovered
MYOGENESIS0.238Inavolisib— uncovered
GLYCOLYSIS0.159Inavolisib— uncovered
MITOTIC_SPINDLE0.155Inavolisib— uncovered
DNA_REPAIR0.103Idelalisib— uncovered
ANGIOGENESIS0.095Remibrutinib— uncovered
G2M_CHECKPOINT0.093Inavolisib— uncovered
NOTCH_SIGNALING0.093Inavolisib— uncovered
HEDGEHOG_SIGNALING0.088Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.085Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.060Inavolisib— uncovered
E2F_TARGETS0.043Inavolisib— uncovered
MYC_TARGETS_V20.036Idelalisib— uncovered
APICAL_JUNCTION0.031Inavolisib— uncovered
KRAS_SIGNALING_DN0.008Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.006Inavolisib— uncovered